Venous Thromboembolism (VTE) afflicts nearly a million Americans yearly, has a mortality of 6-12% and has costs of more than $15 billion. Current treatment regimens, systemic anticoagulation and compression stockings, fail patients in multiple ways: risk of major bleeding episodes; failure of clot resolution in up to 50% of patients; failure to prevent the development of post-thrombotic syndrome (PTS) in up to 40% of ...more »
6 up votes
2 down votes
New paradigms are needed for developing both deliver systems AND drugs to achieve therapeutically effective cell-specific drug delivery.
22 up votes
3 down votes
There is a need to target epigenetic mechanisms as new treatment options for hematologic disorders.
13 up votes
15 down votes